AUS
NZ
UK
CA
USA
IND
Healthcare
Geron Corporation (NASDAQ:GERN) Nasdaq Index Clinical-Stage Biotech Profile
January 23, 2026 12:00 AM PST| By Anmol KhazanchiGeron Corporation (NASDAQ:GERN) focuses on telomerase-based therapies for hematologic malignancies and solid tumors, maintaining visibility in biotechnology discussions connected to the nasdaq index.
Incyte Corporation (NASDAQ:INCY) Nasdaq Top 100 Research Depth
January 23, 2026 12:00 AM PST| By Anmol KhazanchiIncyte Corporation develops targeted therapies in oncology and inflammation, maintaining a global research presence and appearing in broader market discussions connected to the nasdaq top 100.
Aclaris Therapeutics (NASDAQ:ACRS) nasdaq top 100 Clinical Pipeline
January 23, 2026 12:00 AM PST| By Anmol KhazanchiAclaris Therapeutics (NASDAQ:ACRS) develops small-molecule therapies for dermatologic and rare disorders, appearing in broader biotechnology discussions where nasdaq top 100 is cited.
Summit Therapeutics (NASDAQ:SMMT) Nasdaq Index Biotech Research
January 23, 2026 12:00 AM PST| By Anmol KhazanchiSummit Therapeutics plc focuses on precision medicines for serious diseases, developing novel drug candidates through targeted mechanisms, and remains visible in biotechnology conversations shaped by the nasdaq index.
Sarepta Therapeutics (NASDAQ:SRPT) Nasdaq 100 composition Focus
January 23, 2026 12:00 AM PST| By Anmol KhazanchiSarepta Therapeutics develops precision genetic medicines for rare neuromuscular diseases, remaining visible in biotechnology conversations where nasdaq 100 composition highlights research-driven companies.
GH Research (NASDAQ:GHRS) Nasdaq 100 Index Experimental Medicine Pathway
January 23, 2026 12:00 AM PST| By Anmol KhazanchiGH Research Holdings develops novel neuropsychiatric treatments using psychedelic-inspired compounds, appearing in broader biotechnology discussions that include activity associated with the nasdaq 100 index.
Johnson & Johnson (NYSE:JNJ) Dow jones index Global Healthcare Reach
January 23, 2026 12:00 AM PST| By Anmol KhazanchiJohnson & Johnson operates as a global healthcare organization spanning pharmaceuticals and medical devices, maintaining a long-standing presence in discussions connected to the dow jones index.
Kodiak Sciences (NASDAQ:KOD) Concentrates on Vision Preservation
January 23, 2026 12:00 AM PST| By Anmol KhazanchiKodiak Sciences (NASDAQ:KOD) focuses on developing novel retinal disease therapies using antibody biopolymer conjugates, targeting conditions such as wet AMD and diabetic macular edema through advanced clinical research.
Nasdaq Futures Frame Medpace (NASDAQ:MEDP) Clinical Services Role
January 22, 2026 12:00 AM PST| By Anmol KhazanchiMedpace Holdings (NASDAQ:MEDP) delivers end-to-end clinical development services across all trial phases, remaining visible in broader healthcare and market conversations linked to nasdaq futures.
Kura Oncology (NASDAQ:KURA) Nasdaq 100 Index Clinical Research Focus
January 22, 2026 12:00 AM PST| By Anmol KhazanchiKura Oncology (NASDAQ:KURA) develops targeted oncology therapies using precision medicine and molecular biology, appearing in broader biotechnology discussions connected with the nasdaq 100 index.
Aveanna Healthcare (NASDAQ:AVAH) Nasdaq Index Home Health Platform
January 22, 2026 12:00 AM PST| By Anmol KhazanchiHighlights,Aveanna Healthcare delivers home-based clinical services,Pediatric and adult care programs support patient needs,National footprint spans diverse healthcare environments,Aveanna Healthcare, Inc. (NASDAQ:AVAH) operates within the home-based...
Siga Technologies (NASDAQ:SIGA) Nasdaq Top 100 Biomedical Strategy
January 22, 2026 12:00 AM PST| By Anmol KhazanchiSIGA Technologies (NASDAQ:SIGA) develops and commercializes medical countermeasures for public health emergencies and biological threats, appearing in broader market discussions that include the nasdaq top 100.
Lexicon Pharmaceuticals (NASDAQ:LXRX) Aligns Research With Genetics
January 22, 2026 12:00 AM PST| By Anmol KhazanchiLexicon Pharmaceuticals (NASDAQ:LXRX) applies genome biology and large-scale gene research to identify therapeutic targets, advancing novel medicines through structured preclinical and clinical development programs.
Annexon Inc (NASDAQ:ANNX) Advances Complement Biology Platform
January 22, 2026 12:00 AM PST| By Anmol KhazanchiAnnexon Inc (NASDAQ:ANNX) focuses on complement pathway inhibition to address neurodegenerative and neuroimmune disorders, advancing clinical-stage therapies targeting immune-mediated neurological damage.
Doximity (NASDAQ:DOCS) Strengthens Professional Medical Networking
January 21, 2026 12:00 AM PST| By Anmol KhazanchiDoximity (NASDAQ:DOCS) operates the leading professional medical network in the US, enabling physicians and clinicians to collaborate, access clinical news, and communicate securely through a digital platform.
Harrow Health (NASDAQ:HROW) Expanding Clinical Reach In Ophthalmology
January 21, 2026 12:00 AM PST| By Anmol KhazanchiHarrow Health (NASDAQ:HROW) operates as a commercial-stage biopharmaceutical company focused on ophthalmic therapeutics and diagnostics, delivering proprietary, generic, and branded products for ocular conditions.
TG Therapeutics Inc (NASDAQ:TGTX) Nasdaq 100 Etf Biotech Structure
January 20, 2026 12:00 AM PST| By Anmol KhazanchiTG Therapeutics develops targeted therapies for hematological and autoimmune conditions, appearing in broader biotech conversations where the nasdaq 100 etf is mentioned within market-level analysis.
Axsome Therapeutics (NASDAQ:AXSM) Appears In Nasdaq Today CNS Discussions
January 20, 2026 12:00 AM PST| By Anmol KhazanchiAxsome Therapeutics develops novel CNS therapies targeting depression, migraine, narcolepsy, and fibromyalgia, appearing in broader biopharmaceutical discussions shaped by movements linked to nasdaq today.
HUTCHMED Ltd. (NASDAQ:HCM) Strengthens End-to-End Biopharma Model
January 20, 2026 12:00 AM PST| By Anmol KhazanchiHUTCHMED is a fully integrated biopharmaceutical company developing targeted therapies and immunotherapies, combining discovery research, clinical development, manufacturing, and commercialization across multiple disease areas.
Merck & Co., Inc. (NYSE:MRK) S&P 500 Fund Healthcare Scale
January 20, 2026 12:00 AM PST| By Anmol KhazanchiMerck & Co. (NYSE:MRK) supports global healthcare through medicines, vaccines, biologics, and animal health products, appearing in broader market discussions that include the s&p 500 fund.
